Diagnosis and treatment of neurocysticercosis

Nature Reviews Neurology

Volumn 7, Issue 10, 2011, Pages 584-594

  Nash, Theodore E ^a   Garcia, Hector H ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b INSTITUTO NACIONAL DE CIENCIAS NEUROLÓGICAS   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ANALGESIC AGENT; ANTHELMINTIC AGENT; ANTICONVULSIVE AGENT; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; MANNITOL; PRAZIQUANTEL; STEROID;

ANTIINFLAMMATORY ACTIVITY; BASAL SUBARACHNOID NEUROCYSTICERCOSIS; CALCIFICATION; CEREBROSPINAL FLUID FLOW; CLINICAL FEATURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EXTRAPARENCHYMAL NEUROCYSTICERCOSIS; GEOGRAPHIC DISTRIBUTION; GRAY MATTER; HEADACHE; HUMAN; HYDROCEPHALUS; MORBIDITY; MORTALITY; NAUSEA; NEUROCYSTICERCOSIS; NEUROENDOSCOPY; NEUROIMAGING; NONHUMAN; PARENCHYMAL NEUROCYSTICERCOSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEIZURE; SEROLOGY; SURGICAL TECHNIQUE; SYLVIAN FISSURE; TAENIA SOLIUM; VENTRICULAR NEUROCYSTICERCOSIS; VOMITING; WHITE MATTER;

ADRENAL CORTEX HORMONES; ANIMALS; ANTHELMINTICS; ANTI-INFLAMMATORY AGENTS; ANTICONVULSANTS; HUMANS; INFLAMMATION; NEUROCYSTICERCOSIS;

EID: 80555131158     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2011.135     Document Type: Review

References (116)

1. [No authors listed] Relationship between epilepsy and tropical diseases. Commission on Tropical Diseases of the International League Against Epilepsy. Epilepsia 35, 89-93 (1994).
2. Garcia, H. H. & Del Brutto, O. H. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol. 4, 653-661 (2005).
3. Ndimubanzi, P. C. et al. A systematic review of the frequency of neurocyticercosis with a focus on people with epilepsy. PLoS Negl. Trop. Dis. 4, e870 (2010).
4. Montano, S. M. et al. Neurocysticercosis: association between seizures, serology, and brain CT in rural Peru. Neurology 65, 229-233 (2005).
5. Villaran, M. V. et al. Epilepsy and neurocysticercosis: an incidence study in a Peruvian rural population. Neuroepidemiology 33, 25-31 (2009).
6. Medina, M. T. et al. Prevalence, incidence, and etiology of epilepsies in rural Honduras: the Salama Study. Epilepsia 46, 124-131 (2005).
7. Del Brutto, O. H. et al. Epilepsy and neurocysticercosis in Atahualpa: a door to door survey in rural coastal Ecuador. Epilepsia 46, 583-587 (2005).
8. Budke, C. M., White, A. C. Jr & Garcia, H. H. Zoonotic larval cestode infections: neglected, neglected tropical diseases? PLoS Negl. Trop. Dis. 93, 211-221 (2009).
9. Rajshekhar, V., Joshi, D. D, Doanh, N. Q, van De, N. & Xiaonon, Z. Taenia solium taeniosis/cysticercosis in Asia: epidemiology, impact and issues. Acta Trop. 87, 53-60 (2003).
10. Del Brutto, O. H., Sotelo, J. & Roman, G. C. Neurocysticercosis: a Clinical Handbook (Swets & Zeitliger, Lisse) (1998).
11. Schantz, P. M., Wilkins, P. P. & Tsang, V. C. W. in Emerging Infections 2 Ch. 2 (eds Scheld, W. M. et al.) 213-241 (American Society for Microbiology, Washington DC, 1998).
12. Quet, F. et al. Meta-analysis of the association between cysticercosis and epilepsy in Africa. Epilepsia 51, 830-837 (2010).
13. Praet, N. et al. The disease burden of Taenia solium cysticercosis in Cameroon. PLoS Negl. Trop. Dis. 3, e406 (2009).
14. Winkler, A. S. et al. Epilepsy and neurocysticercosis in rural Tanzania-an imaging study. Epilepsia 50, 987-993 (2009).
15. Winkler, A. S., Willingham, A. L. 3rd, Sikasunge, C. S. & Schmutzhard, E. Epilepsy and neurocysticercosis in sub-Saharan Africa. Wien. Klin. Wochenschr. 121 (Suppl. 3), 3-12 (2009).
16. Serpa, J. A., Graviss, E. A., Kass, J. S. & White, A. C. Neurocysticercosis in Houston, Texas: an update. Medicine (Baltimore) 90, 81-86 (2010).
17. Sorvillo, F., Wilkins, P., Shafir, S. & Eberhard, M. Public health implications of cysticercosis acquired in the United States. Emerg. Infect. Dis. 17, 1-6 (2010).
18. Raffaldi, I. et al. An uncommon cause of seizures in children living in developed countries: neurocysticercosis - a case report. Ital. J. Pediatr. 37, 9 (2010).
19. Croker, C., Reporter, R. & Mascola, L. Use of statewide hospital discharge data to evaluate the economic burden of neurocysticercosis in Los Angeles County (1991-2008). Am. J. Trop. Med. Hyg. 83, 106-110 (2010).
20. Gilman, R. H., Del Brutto, O. H., Garcia, H. H. & Martinez, M. Prevalence of taeniosis among patients with neurocysticercosis is related to severity of infection. The Cysticercosis Working Group in Peru. Neurology 55, 1062 (2000).
21. Sarti Gutierrez, E., Schantz, P. M., Aguilera, J. & Lopez, A. Epidemiologic observations on porcine cysticercosis in a rural community of Michoacan State, Mexico. Vet. Parasitol. 41, 195-201 (1992).
22. Lescano, A. G. et al. Taenia solium cysticercosis hotspots surrounding tapeworm carriers: clustering on human seroprevalence but not on seizures. PLoS Negl. Trop. Dis. 3, e371 (2009).
23. Nash, T. E. et al. Treatment of neurocysticercosis: current status and future research needs. Neurology 67, 1120-1127 (2006).
24. Garcia, H. H. et al. Neurocysticercosis: unraveling the nature of the single cysticercal granuloma. Neurology 75, 654-658 (2010).
25. Verma, A. et al. Toll-like receptor 4 polymorphism and its association with symptomatic neurocysticercosis. J. Infect. Dis. 202, 1219-1225 (2010).
26. Lobato, R. D. et al. Hydrocephalus in cerebral cysticercosis. Pathogenic and therapeutic considerations. J. Neurosurg. 55, 786-793 (1981).
27. Carabin, H. et al. Clinical manifestations associated with neurocysticercosis: a systematic review. PLoS Negl. Trop. Dis. 5, e1152 (2011).
28. Antoniuk, S. et al. Neurocysticercosis in children: clinical study and follow-up of 112 patients. Rev. Neurol. 42 (Suppl. 3), S97-S101 (2006).
29. Morales, N. M., Agapejev, S., Morales, R. R, Padula, N. A. & Lima, M. M. Clinical aspects of neurocysticercosis in children. Pediatr. Neurol. 22, 287-291 (2000).
30. Escobar, A. The pathology of neurocysticercosis in Cysticercosis of the Central Nervous System (eds Palacios, E. et al) 27-54 (Thomas, C. C., Springfield, 1983).
31. Evans, C. A. W. The immunology of the host-parasite relationship in Taenia solium Cysticercosis: Implications for Prevention and Therapy in Taenia solium Taeniasis/Cysticercosis 2nd edn (eds Garcia, H. H. & Martinez, S. M) 25-37 (Editorial Universo, Lima, (1999).
32. Nash, T. E. et al. Calcific neurocysticercosis and epileptogenesis. Neurology 62, 1934-1938 (2004).
33. Rajshekhar, V. & Chandy, M. J. (Eds) Solitary Cysticercus Granuloma: the Disappearing Lesion (Orient Longman, Chennai, 2000).
34. Singh, G. & Murthy, J. M. Solitary cysticercus granuloma-treatment with albendazole: what is the optimal duration? Neurol. India 58, 507-508 (2010).
35. Rajshekhar, V., Haran, R. P., Prakash, G. S. & Chandy, M. J. Differentiating solitary small cysticercus granulomas and tuberculomas in patients with epilepsy. Clinical and computerized tomographic criteria. J. Neurosurg. 78, 402-407 (1993).
36. Sharma, P., Garg, R. K., Verma, R., Singh, M. K. & Shukla, R. Risk of seizure recurrence in patients of new-onset partial seizure having a solitary cysticercus granuloma of brain or normal neuroimaging. J. Neurol. Sci. 301, 21-26 (2010).
37. Kramer, L. D., Locke, G. E., Byrd, S. E. & Daryabagi, J. Cerebral cysticercosis: documentation of natural history with CT. Radiology 171, 459-462 (1989).
38. Nash, T. E. & Patronas, N. J. Edema associated with calcified lesions in neurocysticercosis. Neurology 53, 777-781 (1999).
39. Sheth, T. N., Pilon, L., Keystone, J. & Kucharczyk, W. Persistent MR contrast enhancement of calcified neurocysticercosis lesions. AJNR Am. J. Neuroradiol. 19, 79-82 (1998).
40. Ooi, W. W. et al. A calcified Taenia solium granuloma associated with recurrent perilesional edema causing refractory seizures: histopathological features. Am. J. Trop. Med. Hyg. (in press).
41. Nash, T. E., Pretell, J. & Garcia, H. H. Calcified cysticerci provoke perilesional edema and seizures. Clin. Infect. Dis. 33, 1649-1653 (2001).
42. Nash, T. E. et al. Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study. Lancet Neurol. 7, 1099-1105 (2008).
43. Pradhan, S., Kathuria, M. K. & Gupta, R. K. Perilesional gliosis and seizure outcome: a study based on magnetization transfer magnetic resonance imaging in patients with neurocysticercosis. Ann. Neurol. 48, 181-187 (2000).
44. Gupta, R. K., Kathuria, M. K. & Pradhan, S. Magnetisation transfer magnetic resonance imaging demonstration of perilesional gliosis-relation with epilepsy in treated or healed neurocysticercosis. Lancet 354, 44-45 (1999).
45. Escobar, A. et al. The pathology of neurocysticercosis in Taenia Solium Cysticercosis: From Basic To Clinical Science Ch. 30 (eds Singh, G. & Prabhakar, S) 289-305 (Centre for Agricultural Bioscience International, Wallingford, 2002).
46. Henneberg, R. Die tierischen parasiten des zentralnervensystem in Handbuch der Neurologie Vol. 3 (ed. Lewandowsky, M) 643-712 (Springer, Berlin, 1912).
47. Rabiela-Cervantes, M. T. R. et al. Anatomopathological aspects of human brain cysticercosis in Cysticercosis: Present State of Knowledge and Perspectives (eds Flisser, A. et al) 179-200 (Academic, New York, 1982).
48. Marquez-Monter, H. Cysticercosis in Pathology of Protozoal and Helminthic Diseases (ed. Marcial-Rojas, R) 592-617 (Williams & Wilkins, Philadelphia, 1971).
49. Figueroa, J. J., Davis, L. E. & Magalhaes, A. Extraparenchymal neurocysticercosis in Albuquerque, New Mexico. J. Neuroimaging 21, 38-43 (2010).
50. Bandres, J. C., White, A. C. Jr, Samo, T. Murphy, E. C. & Harris, R. L. Extraparenchymal neurocysticercosis: report of five cases and review of management. Clin. Infect. Dis. 15, 799-811 (1992).
51. Proano, J. V. et al. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N. Engl. J. Med. 345, 879-885 (2001).
52. Bickerstaff, E. R., Cloake, P. C., Hughes, B. & Smith, W. T. The racemose form of cerebral cysticercosis. Brain 75, 1-16 (1952).
53. Cardenas, G., Jung, H., Rios, C., Fleury, A. & Soto-Hernandez, J. L. Severe cysticercal meningitis: clinical and imaging characteristics. Am. J. Trop. Med. Hyg. 82, 121-125 (2010).
54. Canelas, H. M., Ricciardi-Cruz, O. & Escalante, O. A. Cysticercosis of the nervous system: less frequent clinical forms. III. Spinal cord forms. Arq. Neuropsiquiatr. 21, 77-86 (1963).
55. Boulos, M. I., Aviv, R. I. & Lee, L. Spinal neurocysticercosis manifesting as recurrent aseptic meningitis. Can. J. Neurol. Sci. 37, 878-880 (2010).
56. Del Brutto, O. H. et al. Proposed diagnostic criteria for neurocysticercosis. Neurology 57, 177-183 (2001).
57. Schantz, P. M. et al. Neurocysticercosis in an Orthodox Jewish community in New York City. N. Engl. J. Med. 327, 692-695 (1992).
58. Del Brutto, O. H. et al. Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology 42, 389-392 (1992).
59. Cruz, M. E., Cruz, I., Preux, P. M., Schantz, P. & Dumas, M. Headache and cysticercosis in Ecuador, South America. Headache 35, 93-97 (1995).
60. Ciampi de Andrade, D. et al. Cognitive impairment and dementia in neurocysticercosis: a cross-sectional controlled study. Neurology 74, 1288-1295 (2010).
61. Garcia, H. H. & Del Brutto, O. H. Imaging findings in neurocysticercosis. Acta Trop. 87, 71-78 (2003).
62. George, U., Bansal, G. & Rathore, S. MR spectroscopy aids diagnosis in subarachnoid space cysticercosis. Neurol. India 58, 957-958 (2010).
63. Dumas, J. L. et al. Parenchymal neurocysticercosis: follow up and staging by MRI. Neuroradiology 39, 12-16 (1997).
64. Wilson, M. et al. Clinical evaluation of the cysticercosis enzyme-linked immunoelectrotransfer blot in patients withneurocysticercosis. J. Infect. Dis. 164, 1007-1009 (1991).
65. Scheel, C. M. et al. Serodiagnosis of neurocysticercosis using synthetic 8 kD proteins: comparison of assay formats. Am. J. Trop. Med. Hyg. 73, 771-776 (2005).
66. Greene, R. M., Hancock, K., Wilkins, P. P. & Tsang, V. C. Taenia solium: molecular cloning and serologic evaluation of 14-and 18-kDa related, diagnostic antigens. J. Parasitol. 86, 1001-1007 (2000).
67. Handali, S. et al. Porcine antibody responses to Taenia solium antigens rGp50 and sTs18var1. Am. J. Trop. Med. Hyg. 71, 322-326 (2004).
68. Handali, S. et al. Development and evaluation of a magnetic immunochromatographic test to detect Taenia solium, which causes taeniasis and neurocysticercosis in humans. Clin. Vaccine Immunol. 17, 631-637 (2010).
69. Handali, S. et al. Multiantigen print immunoassay for comparison of diagnostic antigens for Taenia solium cysticercosis and taeniasis. Clin. Vaccine Immunol. 17, 68-72 (2010).
70. Garcia, H. H. et al. Strategies for the elimination of taeniasis/cysticercosis. J. Neurol. Sci. 262, 153-157 (2007).
71. Diaz, F. et al. Epidemiology of taeniasis and cysticercosis in a Peruvian village. The Cysticercosis Working Group in Peru. Am. J. Epidemiol. 135, 875-882 (1992).
72. Diaz, J. F. et al. Immunodiagnosis of human cysticercosis (Taenia solium): a field comparison of an antibody enzyme linked immunosorbent assay (ELISA), an antigen-ELISA, and an enzyme-linked immunoelectrotransfer blot (EITB) assay in Peru. The Cysticercosis Working Group in Peru (CWG). Am. J. Trop. Med. Hyg. 46, 610-615 (1992).
73. Rodriguez, S. et al. Detection of Taenia solium antigens and anti T. solium antibodies in paired serum and cerebrospinal fluid samples from patients with intraparenchymal or extraparenchymal neurocysticercosis. J. Infect. Dis. 199, 1345-1352 (2009).
74. Bobes, R. J. et al. Subarachnoidal and intraventricular human neurocysticercosis: application of an antigen detection assay for the diagnosis and follow-up. Trop. Med. Int. Health 11, 943-950 (2006).
75. Zamora, H. et al. Drop in antigen levels following successful treatment of subarachnoid neurocysticercosis. Am. J. Trop. Med. Hyg. 73, S41 (2005).
76. Sinha, S. & Sharma, B. S. Neurocysticercosis: a review of current status and management. J. Clin. Neurosci. 16, 867-876 (2009).
77. Garcia, H. H. et al. Current consensus guidelines for treatment of neurocysticercosis. Clin. Microbiol. Rev. 15, 747-756 (2002).
78. Singh, G. et al. A diagnostic and therapeutic scheme for a solitary cysticercus granuloma. Neurology 75, 2236-2245 (2010).
79. Bittencourt, P. R. et al. Phenytoin and carbamazepine decrease oral bioavailability of praziquantel. Neurology 42, 492-495 (1992).
80. Garcia, H. H. et al. Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis. Br. J. Clin. Pharmacol. 72, 77-84 (2011).
81. Mall, R. K., Agarwal, A., Garg, R. K., Kar, A. M. & Shukla, R. Short course of prednisolone in Indian patients with solitary cysticercus granuloma and new-onset seizures. Epilepsia 44, 1397-1401 (2003).
82. Mitre, E., Talaat, K. R., Sperling, M. R. & Nash, T. E. Methotrexate as a corticosteroid-sparing agent in complicated neurocysticercosis. Clin. Infect. Dis. 44, 549-553 (2007).
83. Del Brutto, O. H., Roos, K. L., Coffey, C. S. & Garcia, H. H. Meta-analysis: cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann. Intern. Med. 145, 43-51 (2006).
84. Carpio, A., Santillian, F., Leon, P., Flores, C. & Hauser, W. A. Is the course of neurocysticercosis modified by treatment with antihelminthic agents? Arch. Intern. Med. 155, 1982-1988 (1995).
85. Carpio, A. et al. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J. Neurol. Neurosurg. Psychiatry 79, 1050-1055 (2008).
86. Gonzalez, A. E. et al. Time-response curve of oxfendazole in the treatment of swine cysticercosis. Am. J. Trop. Med. Hyg. 59, 832-836 (1998).
87. Del Brutto, O. H. Medical treatment of cysticercosis-effective. Arch. Neurol. 52, 102-104 (1995).
88. Garcia, H. H. et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N. Engl. J. Med. 350, 249-258 (2004).
89. Vazquez, V. & Sotelo, J. The course of seizures after treatment for cerebral cysticercosis. N. Engl. J. Med. 327, 696-701 (1992).
90. Baranwal, A. K., Singhi, P. D., Khandelwal, N. & Singhi, S. C. Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled, double blind trial. Pediatr. Infect. Dis. J. 17, 696-700 (1998).
91. Kaur, M., Mahajan, R. C. & Malla, N. Diagnostic accuracy of rapid enzyme linked immunosorbent assay for the diagnosis of human hydatidosis. Indian J. Med. Res. 110, 18-21 (1999).
92. Kaur, P., Jost, R., Sivasithamparam, K. & Barbetti, M. J. Comparison of 1 week versus 4 weeks of albendazole therapy in single small enhancing computed tomography lesion. Neurol. India 58, 560-564 (2010).
93. Goel, D., Mittal, M., Bansal, K. K. & Singhal, A. Natural history of solitary cerebral cysticercosis cases after albendazole therapy: a longitudinal follow-up study from India. Acta Neurol. Scand. 121, 204-208 (2010).
94. Padma, M. V., Behari, M. Misra, N. K. & Ahuja, G. K. Albendazole in single CT ring lesions in epilepsy. Neurology 44, 1344-1346 (1994).
95. Rajshekhar, V. Albendazole therapy in patients with solitary cerebral cysticercus granuloma. Is it effective? J. Neurol. Neurosurg. Psychiatry 79, 238-239 (2008).
96. Sotelo, J. et al. Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis. J. Neurol. 237, 69-72 (1990).
97. Corona, T., Lugo, R., Medina, R. & Sotelo, J. Single-day praziquantel therapy for neurocysticercosis. N. Engl. J. Med. 334, 125 (1996).
98. Pretell, E. J. et al. The Cysticercosis Working Group in Peru: failure of one-day praziquantel treatment in patients with multiple neurocysticercosis lesions. Clin. Neurol. Neurosurg. 103, 175-177 (2001).
99. Castro, N. et al. Population pharmacokinetics of albendazole in patients with neurocysticercosis. Int. J. Clin. Pharmacol. Ther. 47, 679-685 (2009).
100. Jung, H. & Gonzalez, D. Pharmacology of antycisticercal therapy in Taenia Solium Cysticercosis: from Basic to Clinical Science (eds Singh, G. & Prabhakar, S.) 363-374 (Centre for Agricultural Bioscience International, Wallingford, 2002).
101. Guo, D. M., Xie, S. P. & Jia, J. P. Therapeutic efficacy of praziquantel, albendazole and a combination of the two drugs in cysticercosis. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 21, 187-188 (2003).
102. Kaur, S., Singhi, P. Singhi, S. & Khandewal, N. Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial. Pediatr. Infect. Dis. J. 28 403-406 (2009).
103. Bittencourt, P. R. et al. High-dose praziquantel for neurocysticercosis: efficacy and tolerability. Eur. Neurol. 30, 229-234 (1990).
104. Bittencourt, P. R., Gracia, C. M., Gorz, A. M. & Oliveira, T. V. High-dose praziquantel for neurocysticercosis: serum and CSF concentrations. Acta Neurol. Scand. 82, 28-33 (1990).
105. Overbosch, D. et al. Penetration of praziquantel into cerebrospinal fluid and cysticerci in human cysticercosis. Eur. J. Clin. Pharmacol. 33, 287-292 (1987).
106. Yee, T., Barakos, J. A. & Knight, R. T. High-dose praziquantel with cimetidine for refractory neurocysticercosis: a case report with clinical and MRI follow-up. West. J. Med. 170, 112-115 (1999).
107. Lima, R. M. et al. Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity. Br. J. Clin. Pharmacol. 71, 528-535 (2011).
108. Agapejev, S., Da Silva, M. D. & Ueda, A. K. Severe forms of neurocysticercosis: treatment with albendazole. Arq. Neuropsiquiatr. 54, 82-93 (1996).
109. Cardenas, G. et al. Subarachnoidal neurocysticercosis non-responsive to cysticidal drugs: a case series. BMC Neurol. 10, 16 (2010).
110. Gongora-Rivera, F. et al. Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis. Neurology 66, 436-438 (2006).
111. Rajshekhar, V. Surgical management of neurocysticercosis. Int. J. Surg. 8, 100-104 (2010).
112. Torres-Corzo, J. G. et al. Endoscopic management of hydrocephalus due to neurocysticercosis. Clin. Neurol. Neurosurg. 112, 11-16 (2010).
113. Jimenez-Vazquez, O. H. & Nagore, N. Cisternal neurocysticercosis. Br. J. Neurosurg. 22, 774-775 (2008).
114. Jimenez-Vazquez, O. H. & Nagore, N. Role of neuroendoscopy in the treatment of large viable cysticerci in the brain parenchyma. Br. J. Neurosurg. 22, 682-683 (2008).
115. Bergsneider, M. Endoscopic removal of cysticercal cysts within the fourth ventricle. Technical note. J. Neurosurg. 91, 340-345 (1999).
116. Bergsneider, M., Holly, L. T., Lee, J. H., King, W. A. & Frazee, J. G. Endoscopic management of cysticercal cysts within the lateral and third ventricles. J. Neurosurg. 92, 14-23 (2000).